Cargando…
Inter- and Intra-patient Variability Over Time of Lesional Skin Microbiota in Adult Patients with Atopic Dermatitis
Atopic dermatitis (AD) is a common chronic, inflammatory skin disorder associated with Staphylococcus aureus colonization and reduced microbiota diversity (1–3). New treatments are being evaluated using clinical AD scores and skin microbiota composition (4–8). Most study designs include the collecti...
Autores principales: | VAN DEN MUNCKHOF, Ellen H. A., NIEMEYER-VAN DER KOLK, Tessa, VAN DER WALL, Hein, VAN ALEWIJK, Dirk C. J. G., VAN DOORN, Martijn B. A., BURGGRAAF, Jacobus, BUTERS, Thomas P., BECKER, Martin J., FEISS, Gary L., QUINT, Wim G. V., VAN DOORN, Leen-Jan, KNETSCH, Cornelis W., RISSMANN, Robert |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Society for Publication of Acta Dermato-Venereologica
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9128996/ https://www.ncbi.nlm.nih.gov/pubmed/31742645 http://dx.doi.org/10.2340/00015555-3373 |
Ejemplares similares
-
Pharmacodynamic Effects of Topical Omiganan in Patients With Mild to Moderate Atopic Dermatitis in a Randomized, Placebo‐Controlled, Phase II Trial
por: Niemeyer‐van der Kolk, Tessa, et al.
Publicado: (2020) -
Omiganan Enhances Imiquimod‐Induced Inflammatory Responses in Skin of Healthy Volunteers
por: Niemeyer‐van der Kolk, Tessa, et al.
Publicado: (2020) -
Treatment with the Topical Antimicrobial Peptide Omiganan in Mild-to-Moderate Facial Seborrheic Dermatitis versus Ketoconazole and Placebo: Results of a Randomized Controlled Proof-of-Concept Trial
por: Rousel, Jannik, et al.
Publicado: (2023) -
Comprehensive, Multimodal Characterization of an Imiquimod‐Induced Human Skin Inflammation Model for Drug Development
por: van der Kolk, Tessa, et al.
Publicado: (2018) -
A systematic literature review of the human skin microbiome as biomarker for dermatological drug development
por: Niemeyer ‐ van der Kolk, T., et al.
Publicado: (2018)